|
|
Volumn 3, Issue 11, 2012, Pages 804-805
|
|
Alzheimers disease: Development of disease-modifying treatments is the challenge for our generation
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMYLOID BETA PROTEIN[1-40];
AMYLOID BETA PROTEIN[1-42];
BETA SECRETASE 1;
BETA SECRETASE INHIBITOR;
DONEPEZIL;
GALANTAMINE;
MEMANTINE;
MK 8931;
NEUROTROPHIN;
RIVASTIGMINE;
TACRINE;
UNCLASSIFIED DRUG;
AMYLOID BETA PROTEIN;
ANTIPARKINSON AGENT;
ASPARTIC PROTEINASE;
BACE1 PROTEIN, HUMAN;
CHOLINESTERASE INHIBITOR;
SECRETASE;
TAU PROTEIN;
ALZHEIMER DISEASE;
BABY BOOMER;
BEHAVIOR DISORDER;
CHOLINERGIC NERVE CELL;
CHOLINERGIC TRANSMISSION;
DEATH;
DRUG INDUSTRY;
EDITORIAL;
FOREBRAIN;
HEALTH CARE COST;
HEALTH CARE SYSTEM;
HEART DISEASE;
HUMAN;
HYPOTHESIS;
MENTAL PATIENT;
MORTALITY;
NERVE CELL PLASTICITY;
NEUROFIBRILLARY TANGLE;
PATIENT CARE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PUNISHMENT;
RISK;
UNITED STATES;
DRUG DEVELOPMENT;
DRUG EFFECT;
ALZHEIMER DISEASE;
AMYLOID BETA-PEPTIDES;
AMYLOID PRECURSOR PROTEIN SECRETASES;
ANTIPARKINSON AGENTS;
ASPARTIC ACID ENDOPEPTIDASES;
CHOLINESTERASE INHIBITORS;
DRUG DISCOVERY;
HUMANS;
MEMANTINE;
TAU PROTEINS;
UNITED STATES;
|
|
EID: 84869828607
PISSN: None
EISSN: 19487193
Source Type: Journal
DOI: 10.1021/cn300190f Document Type: Editorial |
|
Times cited : (15)
|
|
References (6)
|
